Whole genome sequencing of rare olfactory neuroblastoma
The Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have conducted whole genome sequencing (WGS) of a rare nasal tract cancer called olfactory neuroblastoma (ONB).
Analysis of the billions of molecules that make up the patient's normal DNA, and cancerous DNA, discovered genetic mutations that could be future targets of advanced precision-medicine drug development.
Results of the study appeared today in the on-line journal PLoS One.
"Currently, physicians have few choices when formulating a treatment plan for a patient with advanced cancer, especially in cases of rare cancers," said Dr. Glen Weiss, the paper's lead author. He holds joint appointments at TGen and at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and TGen that treats cancer patients with promising new drugs.
"There has been no comprehensive genomic sequencing study to identify mutation profiles of these rare ONB cancers in order to identify therapeutic targets for treating these patients," said Dr. Weiss, Director of Thoracic Oncology at the Virginia G. Piper Cancer Center, and a Clinical Associate Professor in TGen's Cancer and Cell Biology Division.
Personalized medicine involves precise drugs aimed at specific genetic targets intended to shrink, and even eliminate, tumors without the debilitating toxic side effects of conventional chemotherapies.
The study involved a 29-year-old man who presented at the Virginia G. Piper Cancer Center at Scottsdale Healthcare following years of standard-of-care treatment involving surgery, radiation and conventional chemotherapy. His metastatic ONB had continued to mutate and return, resulting in deforming lesions and extensive surgeries that required plastic reconstruction.
His biopsied tumor and blood were analyzed at TGen, which spelled out the billions of individual molecular bases in the DNA of the patient's tumor, and in his normal DNA. A comparison identified several significant gene mutations, including: MAP4K2, SIN3B, TAOK2, KDR, TP53, MYC, and NLRC4. These were selected based on clinical relevance and previously published literature on the target genes and their association with carcinogenesis, or the creation and evolution of cancer.
"The mutated target genes implicate aberrations in DNA repair mechanisms and apoptosis," said Dr. John Carpten, the paper's senior author. He is a Professor and Director of TGen's Integrated Cancer Genomics Division and Deputy Director of Research for TGen. "This work provides novel insights into the underpinnings of a rare but terrible form of cancer. Hopefully we can translate these findings into tools for improved clinical management of rare tumors such as this."
The paper cites the need for additional study of how the ONB cancer mutates and progresses, and how whole genome sequencing can play an important role in future analysis.
"With the reduction in cost, improvement in speed of analysis and with more complete understanding of complex genetic alterations, we anticipate that WGS will be applied in the clinic more frequently to common and rare cancers and will pave the way to personalized medicine," Dr. David Craig, another of the paper's senior authors. He is an Associate Professor and Associate Director of TGen's Neurogenomics Division.
The paper, "Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma," was part of a pilot study entitled, "An Ancillary Pilot Trial Using Whole Genome Tumor Sequencing in Patients with Advanced Refractory Cancer."
The National Foundation for Cancer Research, and the TGen Foundation, funded the study.
"This study represents a milestone in cancer research, and is about better treatments and even cures for cancer through genomics-based personalized medicine," said Franklin C. Salisbury Jr., President of the National Foundation for Cancer Research. "Whole genome sequencing is giving scientists a better understanding of the genetic basis of many cancers. Based on mutations uncovered by sequencing, doctors will be able to identify both existing anti-cancer drugs, or new anti-cancer drugs, designed to target those very mutations. This is Research for a Cure."
Journal reference: PLoS ONE
Provided by The Translational Genomics Research Institute
- First whole-genome lung cancer study set for conference Jul 06, 2011 | not rated yet | 0
- TGen, Virginia G. Piper Cancer Center studying new breast cancer drug Jul 20, 2011 | not rated yet | 0
- New international study targets rare cancer bringing hope for advanced thymic cancer patients Dec 08, 2009 | not rated yet | 0
- Researchers discover microRNA role in brain metastasis Apr 01, 2011 | not rated yet | 0
- Effort aims to spike breast cancer with new approach Mar 11, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011 I'd like to open a discussion thread for version 2 of the draft of my book ''Classical and Quantum Mechanics via Lie algebras'', available online at http://lanl.arxiv.org/abs/0810.1019 , and for the...
- More from Physics Forums - Independent Research
More news stories
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
Genetics May 22, 2013 | 4.5 / 5 (4) | 0 |
University of Minnesota Medical School researchers from the Masonic Cancer Center, University of Minnesota, in partnership with the University's Brain Tumor Program, have developed a new mouse model of malignant peripheral ...
Genetics May 20, 2013 | 5 / 5 (1) | 0 |
Northwestern University scientists have shown a gene involved in neurodegenerative disease also plays a critical role in the proper function of the circadian clock.
Genetics May 16, 2013 | 3 / 5 (1) | 1 |
Informed consent is the backbone of patient care. Genetic testing has long required patient consent and patients have had a "right not to know" the results. However, as 21st century medicine now begins to use the tools of ...
Genetics May 16, 2013 | 5 / 5 (1) | 3 |
Ethicists provide framework supporting new recommendations on reporting incidental findings in gene sequencing
In a paper published in Science Express, a group of experts led by bioethicists in the Center for Medical Ethics and Health Policy at Baylor College of Medicine provide a framework for the new American College of Medical Geneti ...
Genetics May 16, 2013 | not rated yet | 0
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
1 hour ago | 4.7 / 5 (3) | 0 |
Gaucher disease causes debilitating and sometimes fatal neurodegeneration in early childhood. Recent studies have uncovered a link between the mutations responsible for Gaucher disease and an increased risk ...
58 minutes ago | not rated yet | 0 |
Spanish researchers have discovered that the daily clearance of neutrophils from the body stimulates the release of hematopoietic stem cells from the bone marrow into the bloodstream, according to a report published today ...
1 hour ago | not rated yet | 0
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...
1 hour ago | not rated yet | 0
Family caregivers of older adults with dementia are less stressed and their moods are improved on days when dementia patients receive adult day services (ADS), according to Penn State researchers.
1 hour ago | not rated yet | 0